IP Library Granted Patent US 7,985,430
Granted Patent B2
US 7,985,430 · App. 10/536,800 · Granted Jul 26, 2011

Solid mucoadhesive composition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,985,430
App. No.
10/536,800
Granted
Jul 26, 2011
Kind
B2
Abstract

An adhesive solid therapeutic composition containing an active ingredient which is an extract of a plant selected from the group consisting of Sambucus nigra, Centella asiatica and Echinacea purpurea , or mixtures thereof and excipients, said excipients comprising (i) a bulk ingredient (ii) an adhesive polymer of acrylic acid and (iii) polyyinylpyrrolidone.

Claims (15)

1. A muco-adhesive solid therapeutic composition containing an active ingredient that is a mixture of extracts obtained from the plant species Sambucus nigra, Centella asiatica and Echinacea purpurea , and excipients, said excipients comprising a bulk ingredient, an adhesive polymer of acrylic acid and polyvinylpyrrolidone, wherein the muco-adhesive solid therapeutic composition adheres to mucosal tissue.

2. A muco-adhesive solid therapeutic composition according to claim 1 provided in the form of a tablet, wherein the surface of said tablet is partially coated with a non-adhesive material, such that said tablet is provided with a first, adhesive side and a second, coated, non-adhesive side.

3. A muco-adhesive solid therapeutic composition according to claim 1 , comprising the active ingredient in an amount from 5 to 15 percent, lactose in an amount from 50 to 65 percent, an adhesive polymer of acrylic acid in an amount from 10 to 20 percent, and polyvinylpyrrolidone in an amount from 10 to 20 percent, based on the total weight of the composition.

4. A muco-adhesive solid therapeutic composition according to claim 1 further comprising hydroxypropyl cellulose.

5. A muco-adhesive solid therapeutic composition according to claim 2 further comprising hydroxypropyl cellulose.

6. A muco-adhesive solid therapeutic composition according to claim 3 further comprising hydroxypropyl cellulose.

7. A muco-adhesive solid composition according to claim 1 , wherein the muco-adhesive solid composition is structurally suitable for buccal administration.

8. A muco-adhesive solid composition according to claim 1 , wherein the muco-adhesive solid composition is structurally suitable for vaginal administration.

9. A muco-adhesive solid composition according to claim 1 , wherein the muco-adhesive solid composition is structurally suitable for anal administration.

10. A method of treating a mucosal tissue lesion in a patient comprising the step of contacting a mucosal tissue lesion with a therapeutically effective amount of a muco-adhesive solid therapeutic composition containing an active ingredient that is a mixture of extracts obtained from the plant species Sambucus nigra, Centella asiatica and Echinacea purpurea , and excipients, said excipients comprising a bulk ingredient, an adhesive polymer of acrylic acid and polyvinylpyrrolidone.

11. A method according to claim 10 , wherein said mucosal tissue is selected from the group consisting of buccal mucosal tissue, vaginal mucosal tissue, and anal mucosal tissue.

12. A method according to claim 10 , wherein said muco-adhesive composition is provided in the form of a tablet, and wherein a surface of the tablet is partially coated with a non-adhesive material, such that said tablet is provided with a first, adhesive side and a second, coated, non-adhesive side.

13. A method according to claim 12 comprising contacting the first, adhesive side of the tablet with the mucosal tissue lesion, wherein the coated non-adhesive side projects away from said lesion.

14. A method according to claim 12 , wherein an amount of said Sambucus nigra extract ranges between about 0.05 mg to about 15 mg, wherein an amount of said Centella asiatica extract ranges between about 0.05 mg to about 15 mg, and wherein an amount of said Echinacea purpurea extract ranges between about 0.05 mg to about 15 mg.

15. A method according to claim 10 , wherein the step of contacting occurs for a period of time ranging between about 1 hour and about 5 hours.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded May 19, 2025
From: IZUN PHARMACEUTICALS CORPORATION
To: KALMAN, JONATHAN, MR.
Reel/Frame 071152/0608 →
SECURITY INTEREST Recorded Jun 30, 2021
From: IZUN PHARMACEUTICALS CORPORATION
To: JONATHAN KALMAN
Reel/Frame 056716/0583 →
RELEASE OF SECURITY INTEREST Recorded Jan 8, 2019
From: IZUN PHARMACEUTICALS CORPORATION
To: HAHN, ELLIOT F
Reel/Frame 047934/0363 →
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NUMBERS 14193345 AND 15006421 PREVIOUSLY RECORDED AT REEL: 040824 FRAME: 0202. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Dec 28, 2017
From: IZUN PHARMACEUTICALS CORPORATION
To: HAHN, ELLIOT F
Reel/Frame 045032/0099 →
SECURITY AGREEMENT Recorded Dec 6, 2016
From: IZUN PHARMACEUTICALS CORPORATION
To: HAHN, ELLIOT F
Reel/Frame 040824/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2006
From: LEVINE, WILLIAM; SAFFER, ARON
To: IZUN PHARMACEUTICALS CORPORATION
Reel/Frame 018021/0334 →